Navigation Links
BioLife Solutions Announces Record Revenue of $2.2 Million in First Quarter of 2013
Date:5/14/2013

customer was recognized as all future performance obligations associated with the previous license agreements were cancelled with the agreement signed in the first quarter of 2013.

Gross margin as a percentage of revenue decreased to 52.1% in the first quarter of 2013 compared to 58.6% for the same period in 2012 due primarily to the increase in contract manufacturing product sales, which has a higher cost of sales, compared to core product sales, offset by recognition of the license revenue during the quarter with no associated costs.

Operating expenses in the first quarter of 2013 were $0.9 million compared with $0.7 million in the first quarter of 2012. This increase was primarily attributable to additional personnel costs that commenced in the second quarter of 2012, higher corporate costs, higher depreciation and rent costs related to the new facility, and higher office-related expenses.

For the first quarter of 2013, the Company reported operating income of $0.2 million compared to operating loss of $0.2 million in the first quarter of 2012. Net loss was $(7,176), or $(0.00) per share for the first quarter of 2013, compared to a loss of $0.3 million or $(0.00) per share in the first quarter of 2012.

Outlook for 2013The Company continues to expect the following 2013 results:

  • Revenue in the range of $6.5 million to $7.0 million, driven by continued increases in sales to existing core product and contract manufacturing customers, the addition of new customers in the regenerative medicine market as customers continue to move their cell and tissue-based therapies and products through the clinical trial and regulatory approval processes, and continued focus on sales through existing distribution network. The Company does not anticipate additional licensing transactions similar to that concluded in the first quarter.
  • Gross margin as a percentage of revenue of approximately 38% - 41% in 2013, with fluctuation occurring
    '/>"/>

  • SOURCE BioLife Solutions, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
    2. BioLife Solutions 2011 Revenue Up 33%
    3. BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board
    4. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
    5. BioLife Solutions Completes Corporate Facilities Expansion, Build-Out of Additional cGMP Clean Room Manufacturing Suite
    6. BioLife Solutions Announces 2012 Second Quarter Results: Eighth Straight Quarter of Record Revenue
    7. BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
    8. BioLife Solutions Announces 2012 Third Quarter Results: Ninth Straight Quarter of Record Revenue
    9. BioLife Solutions Announces License Agreement
    10. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
    11. ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/20/2014)... Francisco, CA (PRWEB) August 20, 2014 ... Conference is being held on October 29-30 in ... perspectives from industry, academic and government researchers and clinicians ... in the space. , In the twelve years ... one hundred therapies have been introduced with pharmacogenetic information ...
    (Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
    (Date:8/19/2014)... 2014 Cellgen Diagnostics ... to fund a corporate lab for its genetic-based ... development is a critical component in the move ... the implementation of personalized medicine – a more ... , Indiegogo contributions will support Cellgen’s intent to ...
    (Date:8/19/2014)... Aug. 19, 2014 CSSi, the leader in ... announced the formation of the company,s Medical and Clinical ... addition of Dr. William E. Gannon, Jr. ... The MCAB, with Dr. Gannon,s ... therapeutic areas and set strategic goals for the advancement ...
    Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3
    ... ... Probiotics has released a case study that provides a sustainable solution ... evidence of the effectivness of beneficial microbial applications. These results are ... Environmental Protection Agency, who recently agreed to identify and investigate ...
    ... ... in new product launch of Chewy Bite Line expansion to include one of a kind ... Las Vegas, ... keep up with the demand to learn more about their new products at the ASMBS ...
    ... As previously announced on October 24th, 2009 delSECUR sold 100% ... Ontario company, QTECH SYSTEMS INC. in exchange for 49% of shares ... QTECH,s Management Team and the appointment of a new Chief Technology Officer, ... , , ...
    Cached Biology Technology:Effective Odor and Pathogen Control in Livestock Operations Revealed in New Case Study 2delSECUR CORPORATION Announces Organizational Update as QTECH SYSTEMS INC. Expands Leadership Team 2delSECUR CORPORATION Announces Organizational Update as QTECH SYSTEMS INC. Expands Leadership Team 3
    (Date:8/19/2014)... engineers have devised a new implantable tissue scaffold coated ... a few weeks. When applied to bone injuries or ... form new bone that looks and behaves just like ... could offer a dramatic improvement over the current standard ... another part of the patient,s body a painful ...
    (Date:8/19/2014)... neonatal abstinence syndrome (NAS) secondary to in-utero opioid ... withdrawal than others, but the underlying reasons are ... genes are turned on or off) changes have ... Boston University School of Medicine (BUSM) and Boston ... kind study to identify some of these epigenetic ...
    (Date:8/19/2014)... of today,s crocodiles colonised the seas during warm phases ... new Anglo-French study which establishes a link between marine ... a period of more than 140 million years. ... the Universit de Lyon, France and formerly from the ... Nature Communications ., Today, crocodiles are ,cold-blooded, animals ...
    Breaking Biology News(10 mins):Engineering new bone growth 2Engineering new bone growth 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2Evolution of marine crocodilians constrained by ocean temperatures 2
    ... the ongoing mission to train and educate scientists on ... J. Craig Venter Institute,s (JCVI) Eukaryotic Genome Annotation and ... to train 40 United States Agriculture Department (USDA) scientists ... session will focus on the use of JCVI,s eukaryotic ...
    ... Langone Medical Center may have discovered a new targeted ... disease, is a serious genetic disorder occurring predominantly in ... childhood. The new study entitled, "Role of calcium-independent phospholipase ... published in the Proceedings of the National Academy ...
    ... to the successful implantation of a fertilized human egg. ... of the implantation can all affect the outcome of ... University researcher is suggesting that prospective parents and their ... other biomechanical processes play in its success. New studies ...
    Cached Biology News:JCVI program trains USDA scientists on eukaryotic genome analysis 2New potential therapeutic target discovered for genetic disorder -- Barth syndrome 2Engineering bouncing babies, 1 at a time 2
    Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
    Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
    Low melting point. Ideally suited for in gel enzymatic reactions. Gelling temp. 24-28C Melting temp. 65C. EEO 0.12 Resolution 0.5-20 kb; Rnase/Dnase: none detected....
    ...
    Biology Products: